RIGEL PHARMACEUTICALS, INC. Cash and Restricted Cash
RIGEL PHARMACEUTICALS, INC. (RIGL) had Cash and Restricted Cash of $60.87 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60.87M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $24.47M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.64M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $60.87M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $24.47M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $40.64M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $48.59M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $53.46M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $45.78M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $56.75M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $51.69M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $36.05M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $25.57M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $32.79M 10-K · filed 2026-03-03 |
| 2023-09-30 | $45.41M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $48.81M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $40.28M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $24.46M 10-K · filed 2026-03-03 |
| 2022-09-30 | $29.87M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $27.20M 10-Q · filed 2023-08-01 |
| 2022-03-31 | $24.68M 10-Q · filed 2023-05-02 |
| 2021-12-31 | $18.89M 10-K · filed 2025-03-04 |
| 2021-09-30 | $30.40M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $84.82M 10-Q · filed 2022-08-02 |
| 2021-03-31 | $20.05M 10-Q · filed 2022-05-03 |
| 2020-12-31 | $30.37M 10-K · filed 2024-03-05 |
| 2019-12-31 | $22.52M 10-K · filed 2023-03-07 |
| 2018-12-31 | $76.32M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |